CIPLA LTD vs Gujarat Inject Kerala

A side-by-side comparison of CIPLA LTD (CIPLA) and Gujarat Inject Kerala (GUJINJEC) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, CIPLA LTD leads CIPLA vs GUJINJEC on 9 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation40
  • Profitability40
  • Growth· not comparable
  • Size & financial health13
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

CIPLA takes 4/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

29.80
P/E ratio
60.14
3.42
P/B ratio
15.66
0.88%
Dividend yield
0.00%
₹48.02
EPS
₹0.21

Profitability

CIPLA takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

11.60%
Return on equity
0.00%
15.00%
Return on capital
12.54%
21.00%
EBITDA margin
0.00%
13.71%
Net margin
6.43%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

7.37%
Revenue CAGR (3Y) even
10.88%
Profit CAGR (3Y) even

Size & financial health

GUJINJEC takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.16L Cr
Market cap
₹195 Cr
₹28,163 Cr
Revenue
₹1245.45L Cr
₹3,862 Cr
Net profit
₹125.16L Cr
0.00
Debt / equity
0.00
CIPLA LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
  • ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.24%"]
CIPLA LTD full analysis Gujarat Inject Kerala full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.